Dr. Merry Lynn Tetef, MD

Dr. Tetef practices at Saddleback Outpatient Surgery Center Ltd in Santa Monica, California.

Dr. Tetef's NPI, 1194784785, was assigned on March 21, 2006. Dr. Tetef graduated from Harvard Medical School in 1987. Dr. Tetef holds California license G64196.

Dr. Tetef's primary practice is Saddleback Outpatient Surgery Center Ltd, at 1250 16th St, Santa Monica, CA 90404 in Los Angeles County. The practice phone is (949) 472-0244.

Dr. Tetef's primary practice is Saddleback Outpatient Surgery Center Ltd in Santa Monica, California. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Tetef to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tetef practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tetef's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tetef is board certified in medical oncology by the American Board of Internal Medicine. Dr. Tetef is licensed in California.

Dmand AI lists breast cancer, chronic leukemia, colorectal cancer, lung cancer, neutropenia, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Tetef treats.

CMS data shows 11,044 Medicare services from Dr. Tetef across 21 procedure codes in 2024, for 541 Medicare patients. Medicare paid $251,314 for them. Every service was in an office.

CMS counts 541 Medicare patients who saw Dr. Tetef in 2024. The largest group is 65 to 74, with 266 patients. 75% of them have cancer, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.34, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Tetef's median patient age at 67, with 97% women.

In 2024, Dr. Tetef wrote 270 Medicare Part D claims for 117 patients. 77% of them were for generic drugs. CMS names the drug for 200 of them, across 5 drugs with 11 or more claims each, at $487,712 in total drug cost. In 2023, CMS named 229 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Tetef for performance year 2024, reported as part of a group.

Dmand AI links 27 papers to Dr. Tetef, published from 2003 to 2024. 2004 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms and Infusions, Intravenous. Dr. Tetef has published most often in Cancer Chemother Pharmacol. Dr. Tetef's most frequent co-authors are Lucille Leong, MD, Kim A. Margolin, MD and Robert Morgan, MD.

CMS Open Payments shows 2 general payments to Dr. Tetef from 2 drug and device companies from 2016 to 2021. Education make up the largest share, 100% of the total. Pfizer Inc. paid the most, $15.

Dmand AI lists 5 awards for Dr. Tetef, most recently Top Doctors:LA Area in 2013.

Dr. Tetef graduated from Harvard Medical School in 1987. Dr. Tetef is a member of ASCO.

Dr. Tetef is in network with 5 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.